Tumor Mutational Load, CD8+T Cells, Expression of PD-L1 and HLA Class I to Guide Immunotherapy Decisions

被引：1

作者：

Hurkmans, D. ^{[1
]}

Kuipers, M. ^{[2
]}

Smit, J. ^{[2
]}

Van Marion, R. ^{[3
]}

Mathijssen, R. ^{[4
]}

Postmus, P. ^{[2
]}

Hiemstra, P. ^{[2
]}

Aerts, J. ^{[1
]}

Von der Thusen, J. ^{[3
]}

Van der Burg, S. ^{[5
]}

机构：

[1] Erasmus Univ, Med Ctr, Pulmonol, Rotterdam, Netherlands

[2] Leiden Univ, Med Ctr, Pulmonol, Leiden, Netherlands

[3] Erasmus Univ, Med Ctr, Pathol, Rotterdam, Netherlands

[4] Erasmus Univ, Med Ctr, Med Oncol, Rotterdam, Netherlands

[5] Leiden Univ, Med Ctr, Med Oncol, Leiden, Netherlands

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期

关键词：

immune checkpoint inhibitor; NSCLC; predictive biomarkers;

D O I：

10.1016/j.jtho.2019.08.1552

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.04-47

引用

页码：S726 / S726

页数：1

共 50 条

[21] The impact of PD-L1, TGF-β expression and tumor-infiltrating CD8+T cells on clinical outcome of patients with advanced thymic epithelial tumors
Duan, J.
Liu, X.
Chen, H.
Bai, H.
Xu, T.
Cai, S.
Wang, J.
ANNALS OF ONCOLOGY, 2018, 29
[22] Expanding immunotherapy options in cholangiocarcinoma: Role of CD27 against in combination with PD-L1 and MEK inhibition on antitumor effect and CD8+T cells
Bennett, Frances J.
Warren, Emilie A. K.
Hammons, Jacklyn N.
Wittling, Megen C.
Oppat, Kailey M.
Wyatt, Megan M.
Rivera, Guillermo O. Rangel
Azad, Nilofer S.
Yarchoan, Mark
Heumann, Thatcher R.
Keler, Tibor
Maithel, Shishir K.
Paulos, Chrystal M.
Lesinski, Gregory B.
ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S164 - S165
[23] Tumor Mutational Burden and PD-L1 Expression in Hematologic Malignancies
Thomas, Sean D.
Jeong, Ah-Reum
Sakowski, Patrick J.
Sokol, Ethan S.
Kurzrock, Razelle
Goodman, Aaron M.
BLOOD, 2020, 136
[24] Blockade of PD-1 and LAG-3 expression on CD8+T cells promotes the tumoricidal effects of CD8+T cells
Ma, Jiajia
Yan, Shufang
Zhao, Ying
Yan, Huifang
Zhang, Qian
Li, Xinxia
FRONTIERS IN IMMUNOLOGY, 2023, 14
[25] Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status
Camy, Florian
Karpathiou, Georgia
Dumollard, Jean Marc
Magne, Nicolas
Perrot, Jean Luc
Vassal, Francois
Picot, Tiphanie
Mobarki, Mousa
Forest, Fabien
Casteillo, Francois
Hathroubi, Sirine
Froudarakis, Marios
Peoc'h, Michel
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[26] Downregulation of Alloimmunity in Lung Allograft by Eosinophils is Orchestrated by PD-L1 Dependent Contact with CD8+T Cells
Onyema, O. O.
Guo, Y.
Mahgoub, B.
Manafi, A.
Wang, Q.
Criswell, S.
Lannigan, J.
Jacobsen, E. A.
Gelman, A. E.
Kreisel, D.
Krupnick, A. S.
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (04): : S154 - S154
[27] Serum-derived exosomal PD-L1 and tumor-infiltrating CD8+T cell expression for predicting anti-PD-1 response in NSCLC
Shimada, Yoshihisa
Matsubayashi, Jun
Kudo, Yujin
Ohira, Tatsuo
Ikeda, Norihiko
CANCER SCIENCE, 2021, 112 : 370 - 370
[28] PD-L1 & Loss of MHC Class I Expression in Breast Cancer: Implications for Immunotherapy
Dusenbery, Anna
Maniaci, Joseph
Hillerson, Natalie
Dill, Erik
Bullock, Timothy
Mills, Anne
MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 96 - 97
[29] PD-L1 & Loss of MHC Class I Expression in Breast Cancer: Implications for Immunotherapy
Dusenbery, Anna
Maniaci, Joseph
Hillerson, Natalie
Dill, Erik
Bullock, Timothy
Mills, Anne
LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 96 - 97
[30] Tumor mutational burden (TMB) and PD-L1 expression as predictors of response to immunotherapy (IO) in NSCLC.
Castellanos, Emily
Snider, Jeremy
Ali, Siraj Mahamed
Backenroth, Daniel
Albacker, Lee A.
Murugesan, Karthikeyan
Li, Gerald
Frampton, Garrett M.
Alexander, Brian Michael
Carson, Kenneth Robert
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →